Shire Pharmaceuticals Group Plc
Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
Lexington, Massachusetts and Durham, North Carolina (ots/PRNewswire) - Demonstrates ongoing commitment to innovation in ophthalmics for Shire P-321 is a Phase 2 investigational topical treatment for dry eye disease Shire plc (LSE: SHP, NASDAQ: SHPG) and Parion Sciences, Inc. today announced they have entered into an ...
mehr